← All trials
NCT06094140
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 20, 2022
- Primary completion
- Jun 30, 2024
- Completion date
- Jun 30, 2026
- First posted
- Oct 23, 2023
- Last posted
- Oct 23, 2023
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Australasian Gastro-Intestinal Trials GroupLead sponsor
- Australasian Gastro-Intestinal Trials GroupStudy chair
- Walter and Eliza Hall Institute of Medical ResearchCollaborator
- University of New South WalesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.